Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk

SIMPLE SUMMARY: It is important to address the influence of 21-gene Recurrence Score (RS) on chemotherapy decision-making stratified by clinical risk in patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. Our study presented that...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Soong June, Ahn, Sung Gwe, Ji, Jung Hwan, Chu, Chihhao, Kim, Dooreh, Lee, Janghee, Cha, Yoon Jin, Jeong, Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394098/
https://www.ncbi.nlm.nih.gov/pubmed/34439158
http://dx.doi.org/10.3390/cancers13164003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394098/
https://www.ncbi.nlm.nih.gov/pubmed/34439158
http://dx.doi.org/10.3390/cancers13164003

Ejemplares similares